Celcuity To Present at Upcoming Stifel 2025 Healthcare Conference
Rhea-AI Summary
Celcuity (Nasdaq: CELC) will present at the Stifel 2025 Healthcare Conference in New York on November 11-13, 2025. CEO and co-founder Brian Sullivan is scheduled for a fireside chat at 10:00 a.m. ET on Tuesday, November 11, 2025. A live webcast will be available via the provided event link and from the company Investors web page, with a replay posted shortly after the live session.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, CELC declined 2.93%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
MINNEAPOLIS, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the Stifel 2025 Healthcare Conference to be held in New York on November 11-13, 2025.
Brian Sullivan, Chief Executive Officer, and Co-founder of Celcuity, is scheduled for a fireside chat at 10:00 a.m. ET on Tuesday, November 11, 2025. A live webcast of the event will be available using this weblink https://event.summitcast.com/view/cwkmPXkC4dosg6MoG95rxb/TdhPBfiMCSQpwPu5E5FzDS. Alternatively, the live webcast will be accessible from the Investors section of the company's website at https://ir.celcuity.com/events-presentations/ with a replay available shortly after.
About Celcuity
Celcuity is a clinical-stage biotechnology company pursuing development of targeted therapies for treatment of multiple solid tumor indications. The company's lead therapeutic candidate is gedatolisib, a potent, pan-PI3K and mTORC1/2 inhibitor that comprehensively blockades the PI3K/AKT/mTOR (“PAM”) pathway. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3Kα, AKT, or mTORC1 alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- ABC has completed enrollment and reported detailed results for the PIK3CA Wild-Type cohort and has completed enrollment of patients for the PIK3CA mutant cohort. A Phase 3 clinical trial, VIKTORIA-2, evaluating gedatolisib plus a CDK4/6 inhibitor and fulvestrant as first-line treatment for patients with HR+/HER2- ABC is currently enrolling patients. A Phase 1/2 clinical trial, CELC-G-201, evaluating gedatolisib in combination with darolutamide in patients with metastatic castration resistant prostate cancer, is ongoing. More detailed information about Celcuity’s active clinical trials can be found at ClinicalTrials.gov . Celcuity is headquartered in Minneapolis. Further information about Celcuity can be found at www.celcuity.com . Follow us on LinkedIn and X .
View source version of release on GlobeNewswire.com
Contacts:
Celcuity Inc.
Brian Sullivan, bsullivan@celcuity.com
Vicky Hahne, vhahne@celcuity.com
(763) 392-0123
ICR Healthcare
Patti Bank, patti.bank@icrhealthcare.com
(415) 513-1284
FAQ
When will Celcuity (CELC) present at the Stifel 2025 Healthcare Conference?
Who from Celcuity (CELC) is speaking at the Stifel 2025 Healthcare Conference?
How can investors watch the Celcuity (CELC) webcast for the Stifel 2025 Healthcare Conference?
What time is Celcuity's (CELC) fireside chat at the Stifel 2025 Healthcare Conference?
What is Celcuity (CELC) and what does the company focus on?
